» Articles » PMID: 38241490

Stromal Alterations in Patients with Monoclonal Gammopathy of Undetermined Significance, Smoldering Myeloma, and Multiple Myeloma

Abstract

The hallmark of multiple myeloma (MM) is a clonal plasma cell infiltration in the bone marrow accompanied by myelosuppression and osteolysis. Premalignant stages such as monoclonal gammopathy of undetermined significance (MGUS) and asymptomatic stages such as smoldering myeloma (SMM) can progress to MM. Mesenchymal stromal cells (MSCs) are an integral component of the bone marrow microenvironment and play an important role in osteoblast differentiation and hematopoietic support. Although stromal alterations have been reported in MM contributing to hematopoietic insufficiency and osteolysis, it is not clear whether alterations in MSC already occur in MGUS or SMM. In this study, we analyzed MSCs from MGUS, SMM, and MM regarding their properties and functionality and performed messenger RNA sequencing to find underlying molecular signatures in different disease stages. A high number of senescent cells and a reduced osteogenic differentiation capacity and hematopoietic support were already present in MGUS MSC. As shown by RNA sequencing, there was a broad spectrum of differentially expressed genes including genes of the BMP/TGF-signaling pathway, detected already in MGUS and that clearly increases in patients with SMM and MM. Our data may help to block these signaling pathways in the future to hinder progression to MM.

Citing Articles

A proinflammatory response and polarized differentiation of stromal elements characterizes the murine myeloma bone marrow niche.

Ghamlouch H, Gagler D, Blaney P, Boyle E, Wang Y, Avigan J Exp Hematol Oncol. 2025; 14(1):22.

PMID: 40011943 PMC: 11866767. DOI: 10.1186/s40164-025-00606-x.


Exploring the role of circulating proteins in multiple myeloma risk: a Mendelian randomization study.

Lee M, Burley K, Hazelwood E, Moore S, Lewis S, Goudswaard L Sci Rep. 2025; 15(1):3752.

PMID: 39885253 PMC: 11782597. DOI: 10.1038/s41598-025-86222-5.


Lenalidomide and pomalidomide modulate hematopoietic cell expansion and differentiation in the presence of MSC.

Fujii S, Miura Y Int J Hematol. 2024; 120(3):278-289.

PMID: 38995485 PMC: 11362235. DOI: 10.1007/s12185-024-03815-y.


Overlapping Stromal Alterations in Myeloid and Lymphoid Neoplasms.

Bogun L, Koch A, Scherer B, Germing U, Fenk R, Maus U Cancers (Basel). 2024; 16(11).

PMID: 38893194 PMC: 11171322. DOI: 10.3390/cancers16112071.


Is It Possible to Predict Tumor Progression Through Genomic Characterization of Monoclonal Gammopathy and Smoldering Multiple Myeloma?.

Testa U, Leone G, Pelosi E, Castelli G, De Stefano V Mediterr J Hematol Infect Dis. 2024; 16(1):e2024044.

PMID: 38882455 PMC: 11178066. DOI: 10.4084/MJHID.2024.044.


References
1.
Michels T, Petersen K . Multiple Myeloma: Diagnosis and Treatment. Am Fam Physician. 2017; 95(6):373-383. View

2.
Todoerti K, Lisignoli G, Storti P, Agnelli L, Novara F, Manferdini C . Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease. Exp Hematol. 2009; 38(2):141-53. DOI: 10.1016/j.exphem.2009.11.009. View

3.
Reagan M, Ghobrial I . Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin Cancer Res. 2011; 18(2):342-9. PMC: 3261316. DOI: 10.1158/1078-0432.CCR-11-2212. View

4.
Chng W, Dispenzieri A, Chim C, Fonseca R, Goldschmidt H, Lentzsch S . IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2013; 28(2):269-77. DOI: 10.1038/leu.2013.247. View

5.
Ghosh-Choudhury N, Windle J, Koop B, Harris M, Guerrero D, Wozney J . Immortalized murine osteoblasts derived from BMP 2-T-antigen expressing transgenic mice. Endocrinology. 1996; 137(1):331-9. DOI: 10.1210/endo.137.1.8536632. View